Suvorexant
Brand names: Belsomra
At a glance
- Medicare prescriptions, 2024
- 187,800
- Medicare drug cost
- $85.0M
- Average cost per prescription
- $452
- Clinicians who prescribed it
- 8,818
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
BELSOMRA ® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
From the FDA-approved prescribing information (label dated March 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Psychiatry 21.2%
- Family Medicine 19.6%
- Internal Medicine 14.9%
- Psychiatric Nurse Practitioners 12.3%
- Nurse Practitioners 12.1%
- Physician Assistants 5.7%
- Neurology 4.1%
- Sleep Medicine 2.3%
- Pulmonology 1.5%
- Pain Medicine 1.2%
- Child & Adolescent Psychiatry 0.8%
- Geriatric Medicine 0.8%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 29% from 2019 to 2024.
Biggest change by state since 2019
- New York +66%
- Ohio +54%
- Alabama +54%
- Indiana +42%
- Wisconsin +39%
- Missouri (smallest change) +5%
- California (smallest change) +7%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Merck Sharp & Dohme LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | yellow round tablet, 5 mm | 5 |
| 10 mg | green round tablet, 6 mm | 33 |
| 15 mg | white oval tablet, 10 mm | 325 |
| 20 mg | white round tablet, 8 mm | 335 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Jul 2025 · Merck & Co. Inc · Class II
Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep. - Mar 2021 · Cardinal Health Inc. · Class II
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.